Inflammatory Response Research Overview

  • Founded
  • 2011
Founded
  • Status
  • Private
  • Employees
  • 33
Employees
  • Latest Deal Type
  • Angel
  • Latest Deal Amount
  • $150K
Latest Deal Amount

Inflammatory Response Research General Information

Description

Provider of drug development services intended to develop drugs for inflammatory disorders. The company's drug development service focuses on pharmaceutical products for the treatment of inflammatory disorders and conditions and its products are oral combination of levocetirizine and montelukast for the treatment of influenza, enabling patients to recover inflammatory disorders.

Contact Information

Website
www.irrinc.net
Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Primary Office
  • 515 East Micheltorena
  • Suite G
  • Santa Barbara, CA 93103
  • United States
+1 (805) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Inflammatory Response Research Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Angel (individual) 18-Dec-2018 $150K 000 Completed Startup
3. Angel (individual) 20-Nov-2017 00000 00.000 0000 Completed Startup
2. Angel (individual) 04-Oct-2016 $15K $875K Completed Startup
1. Angel (individual) 02-Dec-2014 $860K $860K 00.000 Completed Startup
To view Inflammatory Response Research’s complete valuation and funding history, request access »

Inflammatory Response Research Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 000,000 00.000000 00 00 00 00 0.000
Series A 0,000,000 00.000000 00 00 00 00 00.000
To view Inflammatory Response Research’s complete cap table history, request access »

Inflammatory Response Research Patents

Inflammatory Response Research Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20170173001-A1 Levocetirizine and montelukast in the treatment of inflammation mediated conditions Granted 15-Sep-2014 0000000000
EP-3193875-A4 Levocetirizine and montelukast in the treatment of inflammation mediated conditions Pending 15-Sep-2014 0000000000 0
US-9925183-B2 Levocetirizine and montelukast in the treatment of inflammation mediated conditions Active 15-Sep-2014 0000000000 00
EP-3193875-A1 Levocetirizine and montelukast in the treatment of inflammation mediated conditions Pending 15-Sep-2014 0000000000
JP-2020109128-A Levocetirizine and montelukast in treatment of inflammation mediated condition Pending 15-Sep-2014 A61K31/495 0
To view Inflammatory Response Research’s complete patent history, request access »

Inflammatory Response Research Executive Team (2)

Name Title Board Seat Contact Info
Chandler May MD President & Chief Executive Officer
Loriel May Co-Founder, Board Member & Chief Financial Officer
To view Inflammatory Response Research’s complete executive team members history, request access »

Inflammatory Response Research Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial